Circulation

Targeted RNA Editing to Stop Faulty Heart Protein Causing Enlarged Heart Disease

Updated

Abstract

hpCas13d effectively resolved various human pathogenic sequence variations associated with .

  • Wild-type Cas13d was unable to specifically cleave the heterozygous alleles with single nucleotide variants.
  • hpCas13d, engineered with 3 amino acid substitutions, demonstrated minimized collateral RNA cleavage.
  • In vivo application of hpCas13d in two mouse models successfully suppressed the altered alleles linked to hypertrophic cardiomyopathy.
  • Treatment with hpCas13d prevented cardiac hypertrophy in these models.

Simplified

Key numbers

71.57%
Discrimination Ratio Increase
Discrimination ratio of hpCas13d for human pathogenic SNVs.
76.8±3.3%
Cardiac Function Improvement
Ejection fraction in hpCas13d-treated mice vs. untreated controls.
0.64±0.02 mm
Left Ventricular Thickness Reduction
Left ventricular thickness in hpCas13d-treated mice vs. untreated controls.

Full Text

We can’t show the full text here under this license.

Funding

Competing interests

None.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free